Gout Resource Center

Gout is a very common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. Although the etiology of gout is well understood and effective, inexpensive medications exist to treat gout, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout. New features are added often, so check back frequently.

With more than 40 research abstracts on gout accepted for presentation at ACR Convergence 2021, filtering the noise to get to the key thoughts may be challenging. Lisa Stamp, MBChB, PhD, can help. A rheumatologist, professor of medicine and the associate dean of research at the University of Otago in Christchurch, New Zealand, she has extensively researched the pathophysiology and management of gout. She brings us the highlights in “Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021.’“

Reducing Immunogenicity of Pegloticase ... Click here to view abstract video

Reducing Immunogenicity of Pegloticase ... Click here to view visual abstract summary

Gout, Imaging & Cardiovascular Disease: 2 Experts Discuss Challenging Patients & Advanced Imaging

Experts compare using ultrasound and dual-energy computed tomography (DECT) scan when diagnosing likely gout patients, and discuss the latest insights into the intersection between gout and cardiovascular disease.... [Read More]

Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy

A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.... [Read More]

Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021’

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.... [Read More]

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.... [Read More]

Colchicine: An Ancient Drug with Modern Uses

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550… [Read More]

Case Report: Does Young Woman with Gitelman Syndrome Have Gout?

Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In… [Read More]

Pegloticase Safe & Effective for Patients with Gout on Dialysis

Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.... [Read More]

High Opioid Prescription Rates Seen in Emergency Department-Treated Gout

Acute gout can be very painful, causing patients to seek treatment in the emergency department. A retrospective study of pain interventions for gout in Rhode Island found that nearly 30% of patients received prescriptions for opioid medications over 30 months. Of these prescriptions, over 80% were for patients who had never been exposed to opioids… [Read More]

Bringing Consistency to Gout Terms & Concepts

The umbrella term crystalline disease covers arthritic conditions caused by deposition of crystals and associated inflammatory response, including erythema, edema and intense pain. The two most common crystal-induced arthropathies are gout, an arthritis secondary to inflammation caused by the presence of monosodium urate (MSU) crystals formed through high levels of serum urate, and calcium pyrophosphate… [Read More]

The ACR Releases a New Gout Guideline

In May, the ACR released a new treatment guideline for the management of gout for simultaneous publication in Arthritis & Rheumatology and Arthritis Care & Research.1 Based on evidence from more than 130 published studies, the guideline makes a total of 42 recommendations—of which 16 are strong: It has 27 recommendations for urate-lowering therapy (ULT)… [Read More]

The Latest Advances in Sjögren’s, Scleroderma, RA, Gout & More

ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine… [Read More]

New Study Identifies How Big a Role Diet Plays in Hyperuricemia

Living like a king has its price. And while kings and queens are primarily something of yesteryear, the vast majority of those living in reasonably wealthy nations can now live like kings. Now, back to that price. Gout, once known as the disease of kings, has been around at least since the time of the… [Read More]

Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…... [Read More]

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…... [Read More]